Clinical trial Recruiting at 1 site Observational Ages 10 and up

Cohort study on the natural history of Parkinson's disease in France

Official title: Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)

Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT04888364 · Data updated 2026-11-12

This study is trying to understand how Parkinson's disease changes over time by collecting information and blood samples from patients in France to help find new ways to treat it.

More Parkinson Disease trials

Quick facts

Study typeObservational
Ages10 Years and up
SexAll
Enrollment30000 (estimated)
SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Government
Locations1 site (Paris)
StatusRecruiting
StartedJune 16, 2021
Main results expectedDecember 31, 2032
Study endsDecember 31, 2034
Registry record updatedAugust 20, 2026
Trial IDNCT04888364 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals diagnosed with Parkinson's disease or related parkinsonian syndromes, as well as those at risk of developing PD.

Probably not a fit

Patients who do not have a diagnosis of Parkinson's disease or related syndromes and are not at risk for the disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The NS-PARK cohort aims to describe the natural history of Parkinson's disease (PD) and develop patient stratification models based on the disease's pathophysiological mechanisms. Conducted across expert centers in France, the study collects standardized demographic, diagnostic, and clinical data, including motor and non-motor symptoms, which are updated at each patient visit. Blood samples are also collected for genetic testing and biobanking. This longitudinal cohort will facilitate the understanding of PD progression and support the discovery of new genetic factors influencing the disease.

Why it matters

Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with Parkinson's disease.

How similar studies have gone: Other studies have shown success in understanding Parkinson's disease through cohort approaches, making this a promising continuation of similar research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of Parkinson's disease according to UK PD brain bak criteria
* OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom
* OR Subjects at risk of PD defined as :

No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)

AND for all participants

* Affiliated to social security
* Age \> 10 years

Exclusion Criteria:

* Subject under legal protection
* Subject who do not consent to the research
* for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment

Where it's running

  • Centre 01 Paris
    Paris, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.